RetaMaps
Get updates

Retatrutide vs semaglutide

RetaMaps Editorial· Updated October 1, 2026· Editorial review · Medical review pending
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 1, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs

Semaglutide (Ozempic, Wegovy) is a single-receptor GLP-1 agonist, FDA-approved and in wide use for years. Retatrutide targets GLP-1 plus GIP and glucagon receptors, and remains investigational — per Lilly, available only in clinical trials, plus its physician-requested expanded access program. [5]

More receptors isn't automatically better: it changes both the efficacy profile and the side-effect profile, which is exactly what Phase 3 trials measure.

The numbers, side by side

Cross-trial comparison: different populations, durations and statistical methods. Indicative, not proof. No retatrutide-vs-semaglutide head-to-head in obesity has read out.

Semaglutide 2.4 mg — STEP-1 [2]Semaglutide 7.2 mg — STEP UP [3]Retatrutide 12 mg — TRIUMPH-1 [1]
StatusApprovedApproved Mar 19, 2026Investigational
Duration68 weeks—80 weeks
Mean weight loss~14.9%20.7%28.3% (efficacy estimand)

Two more reference points: the higher 7.2 mg Wegovy dose was approved under the National Priority Voucher pilot just 54 days after filing [3], and in the one direct trial that exists among these mechanisms, tirzepatide (two receptors) beat semaglutide 2.4 mg head-to-head, 20.2% vs 13.7% (SURMOUNT-5). [4]

What it means in practice

Semaglutide is prescribable today, with the deepest real-world safety record of any modern obesity medication and a newly approved higher dose that narrows the efficacy gap. Retatrutide's numbers are larger but come from a drug you cannot get outside a trial or expanded access. If you're weighing "start now vs wait," read Should I wait for retatrutide? and talk to a clinician — many practices in the RetaMaps directory prescribe semaglutide today.

Sources

  1. Lilly/PR Newswire — TRIUMPH-1 topline results (May 21, 2026)
  2. Wilding et al., NEJM — STEP-1 (semaglutide 2.4 mg) (2021)
  3. Novo Nordisk — Wegovy 7.2 mg approved in the US (STEP UP 20.7%) (Mar 19, 2026)
  4. SURMOUNT-5 — tirzepatide vs semaglutide (NEJM) (2025)
  5. Lilly — What to know about retatrutide (updated July 2026)

FAQs

Is retatrutide 'stronger Ozempic'?

No. Semaglutide activates one receptor (GLP-1); retatrutide activates three (GIP, GLP-1, glucagon). More receptors changes both efficacy and side-effect profiles — which is exactly what trials measure.

Can a doctor get me retatrutide early?

Only by enrolling you in a clinical trial or through Lilly's expanded access program, which requires your physician to apply and meet medical criteria.

Which semaglutide dose do the numbers refer to?

STEP-1 tested 2.4 mg weekly (about 14.9% at 68 weeks). A higher 7.2 mg dose (Wegovy HD) was FDA-approved March 19, 2026, with 20.7% mean weight loss in STEP UP.

Find weight-loss providers near you

Browse the practices RetaMaps tracks, or get an email when retatrutide's status changes.

Get updates